Cases
Representative Matters: Commercial Litigation: Represents pharmaceutical manufacturers
retailers in multidistrict litigation arising out of the recall of a commonly prescribed generic medication used for the treatment of hypertension.
Represents a food
supplement flavoring products manufacturer in federal securities fraud litigation arising out of a series of complex corporate transactions
investments.
Representing publicly traded biotherapeutics company in arbitration against contract manufacturer in connection with the development of a vaccine c
idate for the treatment of a common poison.
Represents national bank in federal lawsuit brought by consumer alleging federal
state statutory violations
common law claims.
Represents the developer of mixed-use condominium complexes in related actions against the general contractor, alleging construction defect
various tort claims.
Obtained a preliminary injunction on behalf of publicly traded transportation
logistics conglomerate in civil litigation involving trade secret misappropriation claims.
Cannabis: Cannabis regulatory counsel to manufacturer of hemp-derived CBD products.
Cannabis regulatory counsel to a venture capital firm focused on acquiring
developing businesses specializing in cannabis-related consumer goods.
Regulatory counsel to an aromatherapy
essential oils products manufacturer in connection with the company's entry into the hemp-derived CBD market.
Advised a private credit asset management firm on cannabis-related regulatory matters in connection with its provision of a revolving credit facility to support the capital needs of a publicly traded supplier to businesses in the cannabis industry.
Regulatory/Administrative: Currently represent pharmacy in related civil
criminal enforcement actions arising out of DEA inspections.
Represented The Benchmark Company LLC, acting as underwriter in a $12.5 million offering of preferred stock for Fortress Biotech, Inc. (Nasdaq: FBIOP), a developer of pharmaceutical
biotechnology products
product c
idates.
Represented B. Riley FBR, Inc., acting as sales agent in a $150 million at the market equity offering of common stock for Novavax, Inc. (Nasdaq: NVAX), a late stage biotechnology company focused on the discovery, development
commercialization of vaccines to prevent serious infectious diseases, including a potential COVID-related vaccine.
Represented JMP Securities LLC
Oppenheimer & Co., acting as underwriters in a $25 million public offering of common stock
related warrants for Baudax Bio, Inc. (Nasdaq: BXRX), a pharmaceutical company primarily focused on developing
commercializing innovative products for acute care settings.
Represented JMP Securities LLC, acting as sales agent in a $25 million at the market equity offering of common stock for iCAD, Inc. (Nasdaq: ICAD), a global medical technology company that provides innovative cancer detection
therapy solutions.
